| Contributors: |
Roessner, V; Plessen, K; Rothenberger, A; Ludolph, A; Rizzo, R; Skov, L; Strand, G; Stern, J; Termine, C; Hoekstra, P; Androutsos, C; Aschauer, H; Baird, G; Bos-Veneman, N; Brambilla, A; Cardona, F; Cath, D; Cavanna, A; Czernecki, V; Dehning, S; Eapter, A; Farkas, L; Gadaros, J; Hartmann, A; Hauser, E; Heyman, I; Hedderly, T; Korsgaard, A; Jackson, G; Larsson, L; Martino, D; Menghetti, C; Debes, N; Muller, N; Muller-Vahl, K; Munchau, A; Murphy, T; Musil, R; Nagy, P; Nurnberger, J; Oostra, B; Paschou, P; Pasquini, M; Porta, M; Rickards, H; Robertson, M; Servello, D; Tarnok, Z; Van Der Griendt, J; Verdellen, C; Visser-Vandewalle, V; Wannag, E; Wolanczyck, T |
| Description: |
To develop a European guideline on pharmacologic treatment of Tourette syndrome (TS) the available literature was thoroughly screened and extensively discussed by a working group of the European Society for the Study of Tourette syndrome (ESSTS). Although there are many more studies on pharmacotherapy of TS than on behavioral treatment options, only a limited number of studies meets rigorous quality criteria. Therefore, we have devised a two-stage approach. First, we present the highest level of evidence by reporting the findings of existing Cochrane reviews in this field. Subsequently, we provide the first comprehensive overview of all reports on pharmacological treatment options for TS through a MEDLINE, PubMed, and EMBASE search for all studies that document the effect of pharmacological treatment of TS and other tic disorders between 1970 and November 2010. We present a summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice. This summary is, however, rather a status quo of a clinically helpful but merely low evidence guideline, mainly driven by expert experience and opinion, since rigorous experimental studies are scarce. |